Ketotifen Sopharma

Ketotifen Hydrogen Fumarate, the active ingredient in Ketotifen Sopharma, is a H1 receptor antagonist presented as an oral tablet for systemic use. It is employed to manage allergic conditions and to prevent asthma symptoms in adults and children.

GNH USA supplies Ketotifen Sopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements.

Ketotifen Sopharma is an antihistamine that acts on the H1 receptor pathway to control allergic and asthmatic disorders.

- Allergic rhinitis: reduces nasal congestion, itching and sneezing. - Allergic conjunctivitis: alleviates eye itching, redness and tearing. - Asthma prophylaxis: helps prevent bronchial hyper‑responsiveness and asthma attacks.

Ketotifen Sopharma may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Drowsiness: mild sedation or sleepiness. - Dry mouth: reduced salivation. - Weight gain: modest increase in body weight. - Increased appetite: heightened hunger. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice. - Blood dyscrasias: unexplained bruising or bleeding. - Severe skin reactions: rash, Stevens‑Johnson syndrome. - Cardiac arrhythmia: irregular heartbeat. - Anaphylaxis: acute allergic reaction with airway compromise.

When prescribing Ketotifen Sopharma, healthcare professionals should consider several precautionary measures to ensure safe use.

- Pregnancy: use only if potential benefit outweighs risk; data limited. - Breastfeeding: monitor infant for sedation; drug may pass into milk. - Hepatic impairment: dose adjustment may be required; monitor liver function. - Concomitant CNS depressants: may enhance drowsiness; caution advised. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Ketotifen Sopharma can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors: may increase ketotifen plasma levels, raising risk of toxicity. - Anticholinergic agents: additive dry‑mouth and constipation effects.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Alcohol: can increase drowsiness. - Other antihistamines: may cause additive anticholinergic side effects.